T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia

DISEASE CHARACTERISTICS:

* One of the following diagnoses:

  * Acute myelogenous leukemia (AML) meeting 1 of the following conditions:

    * Failed to achieve first remission after an intensive induction regimen containing an anthracycline and cytarabine
    * In second remission and not enrolled in a protocol for autologous bone marrow transplantation
    * Failed to achieve or sustain second remission
    * In first remission but at high risk of relapse because of 1 of the following factors:

      * High-risk cytogenetic features (monosomy 7,5q-, trisomy 8, or t(9;22))
      * AML secondary to treatment of a prior malignancy and without good-risk cytogenetic features of t(8;21), t(15;17), or inv 16
      * AML secondary to myelodysplastic disease
  * Acute lymphocytic leukemia (ALL) meeting 1 of the following conditions:

    * In second remission with initial relapse occurring within 2 years of diagnosis
    * In first complete remission with high-risk cytogenetics (t(9;22) or t(4;11))
    * In third or subsequent remission
    * Failed to achieve or sustain a second remission
  * Chronic myelogenous leukemia (CML) in first or second chronic phase or accelerated phase
  * Stage IV lymphoblastic lymphoma not in first remission or that failed to achieve a remission within the first 4 weeks of induction therapy
  * Juvenile CML
  * Myelodysplastic syndrome
  * Severe aplastic anemia unresponsive to anti-thymocyte globulin or cyclosporine
* No CNS or skin involvement with leukemia
* No requirement for mediastinal irradiation
* No healthy, HLA-identical related donor of at least 1 year of age or matched unrelated donor available within 4-6 months
* Availability of a healthy, 1-3 HLA-A, -B, and -DR mismatched related donor

  * Willing and able to undergo general anesthesia for marrow donation and a 5-day course of filgrastim (G-CSF) with 2 daily leukaphereses

PATIENT CHARACTERISTICS:

Age:

* Under 50 (50 and over allowed on a case-by-case basis)

Performance status:

* Age 16 and over:

  * Karnofsky 70-100%
* Under age 16:

  * Lansky 50-100%

Hematopoietic:

* Not specified

Hepatic:

* Bilirubin less than 2.0 mg/dL (in the absence of liver involvement)
* AST less than twice normal (in the absence of liver involvement)

Renal:

* Creatinine normal OR
* Creatinine clearance greater than 60 mL/min

Cardiovascular:

* Asymptomatic or LVEF greater than 50% at rest, with improvement during exercise

Pulmonary:

* Asymptomatic or DLCO greater than 50% predicted (corrected for hemoglobin)

Other:

* No known hypersensitivity to mouse protein or chicken egg products
* No active viral, bacterial, or fungal infection
* HIV-1, HIV-2, HTLV-1, and HTLV-2 negative
* No other concurrent medical condition that would preclude transplantation
* Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

Biologic therapy

* See Disease Characteristics

Chemotherapy

* See Disease Characteristics

Endocrine therapy

* Not specified

Radiotherapy

* See Disease Characteristics

Surgery

* See Disease Characteristics